This provides further scientific support to SeaBeLife’s innovative approach to targeting two major pathways involved in pathological cell death: ferroptosis and necroptosis.
The review, co-authored by SeaBeLife co-founders Claire Delehouzé and Stéphane Bach, introduces the concept of ‘NecroFerrins’; molecules designed to simultaneously inhibit ferroptosis and necroptosis, two interconnected forms of regulated cell death.
Published in Ferroptosis and Oxidative Stress, a peer-reviewed journal focusing on the mechanisms and functions of ferroptosis and oxidative stress in health and disease, the review, ‘NecroFerrins as dual therapeutic inhibitors targeting necroptosis and ferroptosis’, explores the emerging concept of molecules capable of simultaneously interfering with both pathways. It proposes that this dual inhibition strategy could offer advantages over approaches focused on a single form of regulated cell death, particularly in diseases where several cell-death mechanisms are activated simultaneously.
Targeting interconnected mechanisms of cell death
Ferroptosis and necroptosis are distinct forms of cell death, but increasing evidence shows that they can interact through common cellular mechanisms, including oxidative stress, redox imbalance, lipid metabolism and inflammatory signaling.
Necroptosis is primarily regulated through the RIPK1–RIPK3–MLKL signaling pathway, while ferroptosis is characterized by iron-dependent lipid peroxidation and the failure of cellular antioxidant defenses. In conditions associated with tissue injury, these pathways may be activated together or compensate for one another, potentially limiting the effectiveness of therapies that inhibit only one pathway.
The review introduces the term ‘NecroFerrins’ to describe small molecules with dual inhibitory activity against ferroptosis and necroptosis. This concept reflects a broader move toward polypharmacology, in which a single therapeutic molecule is designed to modulate multiple biologically connected mechanisms.
Its publication is particularly relevant to our scientific platform, which is built around the hypothesis that simultaneously blocking ferroptosis and necroptosis can provide more comprehensive protection against pathological cell death.
Among the molecules discussed in the review are RIPROStatins, a subclass combining inhibition of RIPK1-dependent necroptosis with radical-trapping antioxidant activity. By bringing together these two complementary activities, such compounds illustrate how a single molecule can potentially intervene at different points within interconnected cell-death pathways.
For SeaBeLife, this scientific perspective reinforces the rationale behind developing therapies that do not focus on a single mechanism of cellular injury, but instead seek to address the complex network of pathways driving tissue damage.
Diseases associated with acute and chronic tissue injury can involve multiple overlapping mechanisms, making the identification of multi-target compounds an increasingly attractive strategy.
The review was published on August 5, 2026, in Ferroptosis and Oxidative Stress :
https://sciexplor.com/fos/articles/fos.2026.0041
Source: EurekAlert – https://www.eurekalert.org/news-releases/1140480